GSK: ACIP recommends GSK's RSV vaccine for at-risk adults 50 to 59
The ACIP has voted to recommend the use of respiratory syncytial virus (RSV) vaccines for adults aged 50 to 59.
Read full article »
GSK is an England-based multinational biopharmaceutical company that develops and markets medicinal drugs and vaccines for the treatment of a variety of diseases.
Read more